News

PharmiWeb6h
Leqembi® (lecanemab) is the First Medicine that…
Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...
pharmaphorum6h
After delay, Alzheimer's drug Leqembi gets green light in EU
The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...
Le Lézard17h
Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (A?) monoclonal antibody Leqembi® ...
Leqembi®âˆ‡ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...
Nurse wins prestigious award, for helping kids with chronic pain
A nurse practitioner whose research at Toronto's Hospital for Sick Children is dedicated to helping children and teens manage ...
These Eight Scientists Have Advanced Our Understanding of Human Health and Disease
Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...
Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story
Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...